Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.

Svatek RS, Ji N, de Leon E, Mukherjee NZ, Kabra A, Hurez V, Nicolas M, Michalek JE, Javors M, Wheeler K, Sharp ZD, Livi CB, Shu ZJ, Henkes D, Curiel TJ.

Cancer Immunol Res. 2018 Dec 18. doi: 10.1158/2326-6066.CIR-18-0336. [Epub ahead of print]

PMID:
30563829
2.

Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer.

Mukherjee N, Ji N, Hurez V, Curiel TJ, Montgomery MO, Braun AJ, Nicolas M, Aguilera M, Kaushik D, Liu Q, Ruan J, Kendrick KA, Svatek RS.

Oncotarget. 2018 Nov 23;9(92):36492-36502. doi: 10.18632/oncotarget.26362. eCollection 2018 Nov 23.

3.

Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.

Padrón Á, Hurez V, Gupta HB, Clark CA, Pandeswara SL, Yuan B, Svatek RS, Turk MJ, Drerup JM, Li R, Curiel TJ.

Exp Gerontol. 2018 May;105:146-154. doi: 10.1016/j.exger.2017.12.025. Epub 2018 Jan 8.

PMID:
29326088
4.

Considerations for successful cancer immunotherapy in aged hosts.

Hurez V, Padrón Á, Svatek RS, Curiel TJ.

Exp Gerontol. 2018 Jul 1;107:27-36. doi: 10.1016/j.exger.2017.10.002. Epub 2017 Oct 4. Review.

PMID:
28987644
5.

Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.

Liu Y, Pandeswara S, Dao V, Padrón Á, Drerup JM, Lao S, Liu A, Hurez V, Curiel TJ.

Cancer Res. 2017 Jan 15;77(2):520-531. doi: 10.1158/0008-5472.CAN-16-1140. Epub 2016 Oct 13.

6.

Considerations for successful cancer immunotherapy in aged hosts.

Hurez V, Padrón ÁS, Svatek RS, Curiel TJ.

Clin Exp Immunol. 2017 Jan;187(1):53-63. doi: 10.1111/cei.12875. Epub 2016 Nov 7. Review.

7.

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJ.

Cancer Res. 2016 Dec 1;76(23):6964-6974. Epub 2016 Sep 26. Erratum in: Cancer Res. 2017 May 15;77(10 ):2770.

8.

Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells.

Dao V, Liu Y, Pandeswara S, Svatek RS, Gelfond JA, Liu A, Hurez V, Curiel TJ.

Cancer Res. 2016 Oct 15;76(20):5970-5982. Epub 2016 Aug 28.

9.

Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.

Patel S, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, Curiel T, Mahalingam D.

Oncotarget. 2016 Sep 13;7(37):59087-59097. doi: 10.18632/oncotarget.10824.

10.

Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.

Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, Hurez V, Conejo-Garcia J, Vadlamudi R, Li R, Curiel TJ.

Signal Transduct Target Ther. 2016;1. pii: 16030. doi: 10.1038/sigtrans.2016.30. Epub 2016 Dec 23.

11.

Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.

Hurez V, Dao V, Liu A, Pandeswara S, Gelfond J, Sun L, Bergman M, Orihuela CJ, Galvan V, Padrón Á, Drerup J, Liu Y, Hasty P, Sharp ZD, Curiel TJ.

Aging Cell. 2015 Dec;14(6):945-56. doi: 10.1111/acel.12380. Epub 2015 Aug 28.

12.

Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage.

Dao V, Pandeswara S, Liu Y, Hurez V, Dodds S, Callaway D, Liu A, Hasty P, Sharp ZD, Curiel TJ.

Cancer Prev Res (Phila). 2015 May;8(5):400-9. doi: 10.1158/1940-6207.CAPR-14-0313-T. Epub 2015 Mar 3.

13.

Immunotherapy for ovarian cancer.

Drerup JM, Liu Y, Padron AS, Murthy K, Hurez V, Zhang B, Curiel TJ.

Curr Treat Options Oncol. 2015 Jan;16(1):317. doi: 10.1007/s11864-014-0317-1. Review.

14.

Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.

Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, Hurez V, Hernandez J, Curiel TJ.

Clin Cancer Res. 2015 Jan 15;21(2):303-11. doi: 10.1158/1078-0432.CCR-14-1781. Epub 2014 Nov 25.

15.

eRapa restores a normal life span in a FAP mouse model.

Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD.

Cancer Prev Res (Phila). 2014 Jan;7(1):169-78. doi: 10.1158/1940-6207.CAPR-13-0299. Epub 2013 Nov 26.

16.

TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-γ-mediated nitric oxide production.

Brumlik MJ, Pandeswara S, Ludwig SM, Jeansonne DP, Lacey MR, Murthy K, Daniel BJ, Wang RF, Thibodeaux SR, Church KM, Hurez V, Kious MJ, Zhang B, Alagbala A, Xia X, Curiel TJ.

Exp Parasitol. 2013 Jul;134(3):389-99. doi: 10.1016/j.exppara.2013.03.016. Epub 2013 Mar 27.

17.

Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.

Hurez V, Daniel BJ, Sun L, Liu AJ, Ludwig SM, Kious MJ, Thibodeaux SR, Pandeswara S, Murthy K, Livi CB, Wall S, Brumlik MJ, Shin T, Zhang B, Curiel TJ.

Cancer Res. 2012 Apr 15;72(8):2089-99. doi: 10.1158/0008-5472.CAN-11-3019. Epub 2012 Apr 11.

18.

Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells.

Sun L, Hurez VJ, Thibodeaux SR, Kious MJ, Liu A, Lin P, Murthy K, Pandeswara S, Shin T, Curiel TJ.

Aging Cell. 2012 Jun;11(3):509-19. doi: 10.1111/j.1474-9726.2012.00812.x. Epub 2012 Mar 22.

19.

Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction.

Tomihara K, Shin T, Hurez VJ, Yagita H, Pardoll DM, Zhang B, Curiel TJ, Shin T.

Aging Cell. 2012 Feb;11(1):128-38. doi: 10.1111/j.1474-9726.2011.00764.x. Epub 2011 Nov 28.

20.

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gribling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, Currie KS.

Nat Chem Biol. 2011 Jan;7(1):41-50. doi: 10.1038/nchembio.481. Epub 2010 Nov 28.

PMID:
21113169
21.

B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses.

Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, Bahar R, Kious MJ, Livi CB, Wall SR, Chen L, Zhang B, Shin T, Curiel TJ.

J Immunol. 2010 Sep 1;185(5):2747-53. doi: 10.4049/jimmunol.1000496. Epub 2010 Aug 4.

22.

Activated Notch2 potentiates CD8 lineage maturation and promotes the selective development of B1 B cells.

Witt CM, Hurez V, Swindle CS, Hamada Y, Klug CA.

Mol Cell Biol. 2003 Dec;23(23):8637-50.

23.
24.

Restricted clonal expression of IL-2 by naive T cells reflects differential dynamic interactions with dendritic cells.

Hurez V, Saparov A, Tousson A, Fuller MJ, Kubo T, Oliver J, Weaver BT, Weaver CT.

J Exp Med. 2003 Jul 7;198(1):123-32. Epub 2003 Jun 30.

25.

Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Hurez V, Hautton RD, Oliver J, Matthews RJ, Weaver CK.

Immunol Res. 2002;26(1-3):131-41. Review.

PMID:
12403352
26.
27.

Paired immunoglobulin-like receptors of activating and inhibitory types.

Kubagawa H, Cooper MD, Chen CC, Ho LH, Alley TL, Hurez V, Tun T, Uehara T, Shimada T, Burrows PD.

Curr Top Microbiol Immunol. 1999;244:137-49. Review. No abstract available.

PMID:
10453656
28.

Paternal monoallelic expression of the paired immunoglobulin-like receptors PIR-A and PIR-B.

Chen CC, Hurez V, Brockenbrough JS, Kubagawa H, Cooper MD.

Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6868-72. Erratum in: Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10294.

29.

Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease.

Hurez V, Kazatchkine MD, Vassilev T, Ramanathan S, Pashov A, Basuyaux B, de Kozak Y, Bellon B, Kaveri SV.

Blood. 1997 Nov 15;90(10):4004-13.

30.

Modulation of autoimmune responses by intravenous immunoglobulin (IVIg).

Kaveri S, Prasad N, Vassilev T, Hurez V, Pashov A, Lacroix-Desmazes S, Kazatchkine M.

Mult Scler. 1997 Apr;3(2):121-8. Review.

PMID:
9291165
31.
32.

Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz D, Kazatchkine MD.

J Clin Invest. 1996 Feb 1;97(3):865-9.

33.

Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).

Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, Kazatchkine MD.

Ther Immunol. 1994 Oct;1(5):269-77.

PMID:
7584501
34.

V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig).

Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, Kaveri SV.

Immunol Rev. 1994 Jun;139:79-107. Review. No abstract available.

PMID:
7927415
35.

Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis.

Saoudi A, Hurez V, de Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD, Druet P, Bellon B.

Int Immunol. 1993 Dec;5(12):1559-67.

PMID:
8312226
36.

Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases.

Hurez V, Kaveri SV, Kazatchkine MD.

J Autoimmun. 1993 Dec;6(6):675-81. Review.

PMID:
8155249
37.

Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis.

Dietrich G, Varela FJ, Hurez V, Bouanani M, Kazatchkine MD.

Eur J Immunol. 1993 Nov;23(11):2945-50.

PMID:
8223872
38.

Prevention of experimental autoimmune uveoretinitis by infusions of human therapeutic intravenous immunoglobulins in rats.

Saoudi A, Hurez V, De Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD, Druet P, Bellon B.

Transplant Proc. 1993 Oct;25(5):2838-9. No abstract available.

PMID:
8212254
39.

Age-related changes in specificity of human natural autoantibodies to thyroglobulin.

Bouanani M, Dietrich G, Hurez V, Kaveri SV, Del Rio M, Pau B, Kazatchkine MD.

J Autoimmun. 1993 Oct;6(5):639-48.

PMID:
7694589
40.

Polyreactivity is a property of natural and disease-associated human autoantibodies.

Hurez V, Dietrich G, Kaveri SV, Kazatchkine MD.

Scand J Immunol. 1993 Aug;38(2):190-6.

PMID:
8346418
41.

Expression and control of the natural autoreactive IgG repertoire in normal human serum.

Hurez V, Kaveri SV, Kazatchkine MD.

Eur J Immunol. 1993 Apr;23(4):783-9.

PMID:
8458369
42.

Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases.

Ronda N, Hurez V, Kazatchkine MD.

Vox Sang. 1993;64(2):65-72. Review.

PMID:
8456559
43.

[Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases].

Mouthon L, Hurez V, Kazatchkine M.

Ann Med Interne (Paris). 1993;144(8):506-13. Review. French.

PMID:
8179238
44.

Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD.

Clin Exp Immunol. 1991 Nov;86(2):192-8. Review. Erratum in: Clin Exp Immunol 1992 May;88(2):373.

Supplemental Content

Support Center